A Study of LY4006896
Phase 1
127
about 3 years
30–85
11 sites in CA, FL, MI +2
What this study is about
This trial is testing a treatment called LY4006896 in people with Parkinson's disease and healthy adults. The goal is to see if this treatment is safe and how it works in the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take LY4006896
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants with One or More SAEs Part B, Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part A, Number of Participants with One or More TEAEs Part B, Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) Part A
Secondary: PK: AUC of LY4006896 ARC-Associated Antisense Part B, PK: Area Under the Concentration versus Time Curve (AUC) of LY4006896 ARC-Associated Antisense Part A, PK: Cmax of LY4006896 ARC-Associated Antisense Part B, Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4006896 ARC-Associated Antisense Part A
Neurology